Capricor (CAPR) Receives FDA RMAT Designation for Duchenne Muscular Dystrophy Therapy

February 5, 2018 7:09 AM

Capricor Therapeutics (NASDAQ: CAPR) today announced that the U.S. Food and Drug Administration (FDA) has granted CAP-1002, its lead investigational ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found